Patient with Type 2 diabetes, proliferative diabetic retinopathy, traction retinal detachment, and age-related cataracts ...

Ocular Therapeutix, Inc.’s OCUL share price has surged by 6.02%, which has investors questioning if this is right time to ...

EyePoint Pharmaceuticals, Inc.’s EYPT share price has surged by 6.87%, which has investors questioning if this is right time ...

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc. (“Opus Genetics” or the “Company”) ...

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...

Dr. Michael Kapusta, MD, FRSCS, Ophthalmologist, talks about advanced (proliferative) diabetic retinopathy and pars plana ...

an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR). Diabetic retinopathy affects more than 100 million people worldwide and is one of the leading causes of ...

an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR). Diabetic retinopathy affects more than 100 million people worldwide and is one of the leading causes of blindness ...